Row
M
MRKAI Stock Diagnostic Report
Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
Following the clinical success of the cancer vaccine co-developed with Moderna, Merck (MRK) was upgraded by Morgan Stanley, but downgraded by RBC Capital Markets due to valuation concerns.
View Source Article ↗AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time